Atopic dermatitis (AD) is the most frequent disease treated at the Avène hydrotherapy center. Children represent a large part of the population due to the high prevalence of AD in early childhood. Avène thermal spring water (ATSW) has been known for its therapeutic effects since the middle of the 18 century. It has been greatly studied over the last decades, with a comprehensive fundamental, pharmaco-clinical and clinical approach. Cohort studies using the Scoring Atopic Dermatitis (SCORAD) clinical score and the Dermatology Life Quality Index (DLQI) or the Children's Dermatology Life Quality Index [CDLQI]) quality of life scores, allowed to confirm the clinical results obtained from the previous studies. These results were corroborated by clinical trials conducted in atopic patients outside the Avène hydrotherapy center, allowing to demonstrate the specific effect of the ATSW. Pharmacological and pharmaco-clinical studies evidenced several effects that could explain the healing effect of ATSW: effect on histamine release, anti-inflammatory effects on standardized models, immuno-modulation of some cytokines involved in DA physiopathology (interferon [INF], interleukin 2 and 4 [IL-2, IL-4]), improvement of keratinocyte differentiation, effect on the skin microbioma by promoting the development of a diversified non-pathogenic flora. In addition, an original microorganism, Aquaphilus dolomiae, never described in another medium, has very recently been identified in the ATSW. Aquaphilus dolomiae is responsible for significant pharmacological activities on inflammation, pruritus and enhancement of innate immunity. This set of works confirms the medical significance of the hydrotherapy which should be considered as a complementary care in the sometimes difficult management of AD.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/S0151-9638(17)31040-2 | DOI Listing |
J Eur Acad Dermatol Venereol
February 2025
CIRI (International Center for Infectiology Research) INSERM U1111, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1 CNRS UMR5308, Lyon, France.
Vet Sci
December 2024
Interactions Cells Environment, 2016. A104, VetAgro Sup, Dermatology Department, 69280 Marcy L'étoile, France.
Evaluation of skin inflammation biomarkers in canine atopic dermatitis (AD) currently requires skin biopsies. Tape stripping has been shown to be a reliable technique to study biomarkers in the stratum corneum (SC) in humans. The aim of this study was to assess the immune response and identify biomarkers in the SC of dogs with canine AD using D-squame as a minimally invasive technique.
View Article and Find Full Text PDFCells
January 2025
Department of Medical Sciences, Graduate School of The Catholic University of Korea, Seoul, #222 Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea.
Cannabinoid compounds have potential as treatments for a variety of conditions, with cannabigerol (CBG) being known for its anti-inflammatory properties. In this study, we investigated the effects of CBG in a cellular model of 1-chloro-2,4-dinitrobenzene (DNCB)-induced atopic dermatitis (AD). In the cellular model, we confirmed the cytotoxicity of CBG and downregulated the expression of inflammatory markers , , , and ( < 0.
View Article and Find Full Text PDFFront Public Health
January 2025
Dermatology Department, Colentina Clinical Hospital, Bucharest, Romania.
Introduction: Atopic dermatitis (AD), a common dermatological condition, is often associated with significant economic and social burdens. Despite extensive studies globally, there is a gap in understanding the impact of this condition in Romania. This study evaluated the economic burden of AD in Romania, considering both direct and indirect costs.
View Article and Find Full Text PDFIndian Dermatol Online J
December 2024
Department of Dermatology, Weill Cornell Medicine, New York, NY, USA.
Background: Inflammatory dermatological conditions, including psoriasis, lichen planus, eczema, and alopecia areata, are frequently accompanied by nail findings and can have a significant impact on quality of life. Biologic and small-molecule medications have been approved over the past several decades in treating patients with these inflammatory nail disorders. They may be used in conjunction with longstanding mainstays of treatment (topical and intralesional corticosteroids, topical vitamin D3 analogs).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!